Latest Research
All publications from the Cancer3.AI database, newest first.
Genomic evolution and natural history of myeloproliferative neoplasms on therapy.
Leongamornlert D, et al
Researchers investigated the genomic evolution of Philadelphia-negative myeloproliferative neoplasms — chronic blood cancers that can progress to myelofibrosis or acute myeloid leukemia — by performing longitudinal whole-genome and targeted sequencing in 30 patients and integrating clonal dynamics with nearly 8,000 blood counts and detailed clinical histories. The study identified distinct genomic evolutionary patterns that reliably distinguish patients with stable disease, who maintain long-term clonal equilibrium without acquiring new cancer-driving mutations, from those destined to progress, in whom leukemic transformation arises through TP53 loss, stepwise accumulation of driver mutations, or emergence of independent leukemic clones. Crucially, disease progression was shown to be genomically encoded years before clinical symptoms appear, suggesting that serial genomic monitoring could serve as a powerful early-warning tool for clinicians. Phylogenetic analysis of 203 whole-genomes from haematopoietic colonies revealed that some cases of triple-negative essential thrombocythaemia reflect age-appropriate polyclonal haematopoiesis and germline predisposition rather than true neoplasia, challenging their classification as cancer. The study also uncovered therapy-associated mutational signatures in blood cells — C>G mutations linked to azacitidine and T>A or T>G changes linked to hydroxycarbamide — raising important questions about the long-term mutagenic consequences of standard MPN treatments that require further investigation.
Cancer discovery
Source →Development and validation of the Essen Melanoma Quality of Life Inventory (EMQoLI).
Musche V, et al
Researchers in Essen, Germany, developed and validated a new patient-reported outcome instrument called the Essen Melanoma Quality of Life Inventory (EMQoLI), designed to comprehensively capture health-related quality of life in melanoma patients receiving modern treatments such as targeted therapy and immunotherapy. The study enrolled 387 German-speaking patients diagnosed with malignant melanoma across all tumor stages to rigorously test the tool's psychometric properties. Through exploratory factor analysis, the researchers identified a three-factor structure and refined the questionnaire from its original item pool to a final 25-item version rated on a five-point Likert scale, demonstrating satisfactory reliability, internal consistency, and both convergent and discriminant validity. Unlike older quality-of-life instruments that focus predominantly on side effects of surgery and chemotherapy, the EMQoLI specifically captures adverse events associated with newer therapies, filling a critical gap in melanoma-specific outcome measurement. The tool is intended to help clinicians efficiently identify patients who may benefit from psychosocial support and to serve as a standardized measure in clinical research and routine care. This development represents an important step toward more patient-centered management of melanoma across all disease stages.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Source →Sex Differences in Loss in Life Expectancy in Primary Cutaneous Melanoma, a Swedish Cohort Study.
Oksanen A, et al
A large Swedish population-based cohort study investigated sex differences in life expectancy and loss in life expectancy among patients diagnosed with invasive cutaneous melanoma, using data from the Swedish Melanoma Registry covering more than 25,000 patients aged 40 and older diagnosed between 2000 and 2014. Researchers found that men with melanoma had an average remaining life expectancy of 15.45 years after diagnosis compared to 20.14 years for women, and men lost approximately 2.95 years of life due to their cancer compared to 2.4 years for women. Crucially, if men had the same relative survival rates as women, their loss in life expectancy would fall to just over one year, revealing a substantial and largely unexplained survival disadvantage for male patients. Standard clinical factors such as patient age, tumor stage, and tumor location were insufficient to account for these sex-based differences. These findings carry important implications for clinicians, suggesting that biological or behavioral factors specific to sex must be investigated to understand and ultimately reduce the survival gap between male and female melanoma patients.
Acta dermato-venereologica
Source →[Orbital metastasis of cutaneous malignant melanoma].
Abdesselam I, et al
This publication examines orbital metastasis arising from cutaneous malignant melanoma, a rare but clinically significant complication in which melanoma cells originating in the skin spread to the bony orbit surrounding the eye. Orbital involvement can manifest as proptosis, diplopia, pain, or visual disturbance, and may represent the first sign of systemic disease progression in some patients. The study underscores the diagnostic challenge ophthalmologists and oncologists face when evaluating orbital masses in patients with a known or occult history of melanoma. Early recognition of orbital metastasis is essential for accurate staging, appropriate systemic treatment planning, and optimal preservation of visual function. This work serves as an important clinical reminder that cutaneous melanoma can disseminate to unusual anatomical sites, requiring multidisciplinary vigilance throughout patient follow-up.
Journal francais d'ophtalmologie
Source →Unexpected localized pleural metastasis without pathologically confirmed nodal involvement in a central ALK-rearranged lung adenocarcinoma: a case report.
Xu Y, et al
This case report published in the Journal of Cardiothoracic Surgery describes an atypical presentation of lung cancer in a 74-year-old man whose small, early-stage tumor unexpectedly revealed pleural metastases during minimally invasive surgery. Preoperative CT imaging classified the 1.5 cm right upper lobe nodule as clinical stage IA2 disease with no signs of pleural contact or lymph node involvement, yet video-assisted thoracoscopic surgery uncovered four to five nodular lesions on the superior mediastinal pleura. Frozen-section and final pathological analysis confirmed poorly differentiated pulmonary adenocarcinoma harboring an ALK gene rearrangement, while all dissected lymph nodes at multiple stations were completely free of metastatic disease — an unusual pattern because nodal spread typically precedes or accompanies pleural dissemination in non-small cell lung cancer. The planned pulmonary resection was abandoned intraoperatively, and the patient was started on the ALK inhibitor alectinib at 600 mg twice daily, achieving marked tumor shrinkage and maintained disease control at six-month follow-up. This case highlights that ALK-rearranged lung cancers may exhibit biologically distinct dissemination pathways, and it underscores the critical importance of intraoperative assessment combined with molecular testing to guide individualized treatment decisions.
Journal of cardiothoracic surgery
Source →